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Annual seasonal influenza epidemics of variable severity are associated with substantial 
morbidity and mortality worldwide, with influenza activity peaking during corresponding 
winter months in temperate climates of the northern and southern hemispheres (1). In the 
tropics and subtropics, influenza activity occurs year-round, with differences in peak 
periods. Most influenza disease burden estimates are derived from studies conducted in 
developed countries. Certain populations are considered to be at increased risk for influenza 
complications, including infants, the elderly, immuno-suppressed persons, pregnant women, 
and persons with chronic conditions including pulmonary and cardiac disease (2). 
Prevention of influenza in the United States is focused upon annual influenza vaccination of 
all persons ≥6 months of age, although recommended target populations and different kinds 
of vaccines and their availability and uses differ worldwide (3). Influenza vaccine 
effectiveness varies by age group, immune status, and antigenic similarities between 
circulating influenza virus strains and vaccine strains.
The World Health Organization has estimated that an estimated 3 to 5 million cases of 
severe influenza and approximately 250,000 to 500,000 deaths occur each year (4). Heart 
failure (HF) is an independent prognostic factor for influenza- associated hospitalization or 
death (5). In the United States, hospitalizations for HF peak during the winter and are lowest 
during the summer (6). Influenza vaccination has been associated with reductions in HF 
hospitalization and death in multiple community-based observational studies of patients ≥65 
years of age and studies of younger adults with high-risk medical conditions (7,8). The U.S. 
Centers for Disease Control and Prevention, American Heart Association, and European 
Society of Cardiology recommend annual influenza vaccinations in patients with HF.
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In this issue of JACC:
Heart Failure, Vardeny et al. (9) assessed influenza vaccination and outcomes in HF patients 
by using data from the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI 
to Determine Impact on Global Mortality and Morbidity in Heart Failure), which 
randomized 8,442 people with systolic HF to sacubitril and valsartan or enalapril therapy 
(10). At enrollment, participants were asked about receipt of influenza vaccination in the 
previous 12 months, and clinical outcomes were assessed during trial follow-up. Among 
21% of participants who reported receiving influenza vaccination, vaccination coverage 
varied widely among different countries, and HF patients who reported being vaccinated had 
lower mortality.
How might influenza vaccination improve out-comes in HF patients? Patients with HF have 
limited reserve with which to tolerate respiratory compromise, and prevention of influenza 
by vaccination as well as reduction of secondary influenza-associated bacterial pneumonia 
may reduce HF exacerbations. Influenza may be a trigger for myocardial infarction, which 
may either precipitate HF or lead to severe illness in those with pre-existing HF; 2 
randomized, controlled trials of influenza vaccination in patients with established coronary 
disease reported efficacy against cardiovascular death (11). Other potential causes of 
influenza-associated myocardial damage include accelerated atherosclerosis related to 
inflammatory response to influenza or to a viral or autoimmune myocarditis.
Influenza vaccination was associated with lower mortality in the PARADIGM-HF trial, but 
as the authors note, causality cannot be determined by the observational study design. 
Patients who received influenza vaccination may be more likely to seek other preventive 
measures. Conversely, older and sicker patients and those with functional impairment may 
be less able to obtain influenza vaccination and more likely to experience severe influenza 
complications. Older patients and those with HF can have a blunted immune response to and 
lower effectiveness of influenza vaccination (12,13), despite a good antigenic match. 
Confounding biases can exaggerate the apparent benefit of influenza vaccination in 
observational studies, including reporting that influenza vaccination was associated with 
lower mortality among elderly people prior to the onset of the influenza season (14). 
Nevertheless, the benefit of influenza vaccination remains significant, even after adjusting 
for potentially large confounders over multiple influenza seasons in observational studies 
(15), as well as in a systematic review of 4 randomized controlled trials (16). Randomized 
controlled trials of influenza vaccination among groups at increased risk for influenza 
complications are unethical in countries that recommend vaccination of these high-risk 
populations. Therefore, evidence from observational studies, surveillance data, modeling, 
and indirect measures are used to provide estimates of influenza disease burden and vaccine 
effectiveness.
Several additional observations deserve comment. First, a higher proportion of participants 
who reported receiving influenza vaccination resided in developed countries with more 
availability of medical facilities, which may have accounted for higher frequency of HF 
hospitalizations and specific cardiac care that reduces mortality. Second, patients who were 
not vaccinated had higher New York Heart Association functional class, higher B-type 
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natriuretic peptide levels, more baseline HF hospitalizations, and lower use of beta-blockers, 
angiotensin-converting enzyme inhibitors, implantable cardioverter defibrillators, and 
cardiac resynchronization therapy; and these differences in HF may also have influenced 
overall outcomes. Finally, self-reported influenza vaccination in the previous 12 months 
might be inaccurate compared to confirming vaccination status from records and, even if 
reliable, might misclassify immunization status. For example, a Canadian patient enrolled in 
May who was vaccinated during the previous 12 months might not be protected from 
influenza in the subsequent winter when follow-up outcomes data were collected, unless 
revaccinated. Therefore, it is challenging to estimate the benefit of influenza vaccination to 
HF patient outcomes from this study, but the findings are consistent with those from other 
studies that have reported the effectiveness of influenza vaccination in other cardiac patients 
(16).
Not surprisingly, enrolling country was the most significant predictor of influenza 
vaccination, and there was a correlation between proportion of influenza-vaccinated 
participants and the country’s gross domestic product. Participants from the most populous 
countries (i.e., China and India) had <1% vaccination coverage, and East and Southeast 
Asian countries had vaccination coverage of <10%. The lack of local data for influenza 
burden and vaccine efficacy in the most low- and middle-income countries, particularly in 
Asia and Africa, has hampered development of national influenza policies. Macro-
epidemiologic studies have shown that public reimbursement is associated with higher 
influenza vaccination coverage (17), and persons living in developed countries and countries 
with national influenza vaccination programs may be more able to access vaccines through 
the public sector. More accurately determining influenza disease burden in developing and 
tropical/subtropical countries can provide data for policy makers to consider influenza 
vaccination programs.
Although influenza may trigger HF exacerbation that requires hospitalization, other 
respiratory pathogens are also associated with HF. However, in HF patients with influenza, 
antiviral treatment with a neuraminidase inhibitor started as soon as possible may confer 
clinical benefit in addition to management of HF. One large meta-analysis of adults 
hospitalized with the influenza A(H1N1)pdm09 virus infection reported that neuraminidase 
inhibitor antiviral treatment compared to no treatment and early initiation of antiviral 
treatment versus later treatment were associated with reductions in mortality risk (18). 
Availability of antiviral agents and supportive intensive care may improve survival in 
critically ill influenza patients.
Overall, this study extends observations from previous studies by providing evidence of 
clinical benefit of influenza vaccination and supports the current strategy to vaccinate HF 
patients. The question is, how can influenza vaccination coverage be increased in HF and 
other cardiac patients? If influenza vaccine is not available or not recommended for cardiac 
patients in a country, then data are needed on influenza disease burden and the economic 
impact of influenza for policymakers. Who should be responsible for ensuring annual 
influenza vaccination of these patients–primary care providers or cardiologists or both? 
Other strategies to increase influenza vaccination, such as standing orders for influenza 
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vaccination of cardiac patients at hospital discharge, and annual influenza vaccination of 
household contacts of HF and other cardiac patients should be considered.
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